Caribou_logo.png
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023 16:00 ET | Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 -- ...
Caribou_logo.png
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
November 06, 2023 08:00 ET | Caribou Biosciences, Inc.
-- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading...
Caribou_logo.png
Caribou Biosciences to Participate in Upcoming Investor Conferences
November 01, 2023 16:05 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
CB-012, a genome-edited allogeneic anti-CLL-1 CAR-T cell therapy with both checkpoint disruption and immune cloaking
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
October 18, 2023 08:00 ET | Caribou Biosciences, Inc.
-- AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 -- -- CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the...
Reigin Zawadzki, chief people officer, Caribou Biosciences
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
September 27, 2023 08:00 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
Caribou_logo.png
Caribou Biosciences to Participate in Upcoming Investor Conferences
August 29, 2023 16:00 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou_logo.png
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023 16:00 ET | Caribou Biosciences, Inc.
-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1...
Caribou_logo.png
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
July 13, 2023 23:15 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of...
Caribou_logo.png
Caribou Biosciences Announces Proposed Public Offering of Common Stock
July 13, 2023 16:03 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has...
ANTLER Phase 1 trial of CB-010
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
July 13, 2023 16:01 ET | Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR)...